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nausea? Protocol of a randomized double blind,
placebo-controlled trial
Wolfgang Marx1,2,10*, Alexandra L McCarthy3,4, Karin Ried2, Luis Vitetta5,6, Daniel McKavanagh7, Damien Thomson8,
Avni Sali2 and Liz Isenring1,9,10Abstract
Background: Preliminary research shows ginger may be an effective adjuvant treatment for chemotherapy-induced
nausea and vomiting but significant limitations need to be addressed before recommendations for clinical practice
can be made.
Methods/Design: In a double–blinded randomised-controlled trial, chemotherapy-naïve patients will be randomly
allocated to receive either 1.2 g of a standardised ginger extract or placebo per day. The study medication will be
administrated as an adjuvant treatment to standard anti-emetic therapy and will be divided into four capsules per
day, to be consumed approximately every 4 hours (300 mg per capsule administered q.i.d) for five days during the
first three cycles of chemotherapy. Acute, delayed, and anticipatory symptoms of nausea and vomiting will be
assessed over this time frame using a valid and reliable questionnaire, with nausea symptoms being the primary
outcome. Quality of life, nutritional status, adverse effects, patient adherence, cancer-related fatigue, and
CINV-specific prognostic factors will also be assessed.
Discussion: Previous trials in this area have noted limitations. These include the inconsistent use of standardized
ginger formulations and valid questionnaires, lack of control for anticipatory nausea and prognostic factors that
may influence individual CINV response, and the use of suboptimal dosing regimens. This trial is the first to address
these issues by incorporating multiple unique additions to the study design including controlling for CINV-specific
prognostic factors by recruiting only chemotherapy-naïve patients, implementing a dosing schedule consistent with
the pharmacokinetics of oral ginger supplements, and independently analysing ginger supplements before and
after recruitment to ensure potency. Our trial will also be the first to assess the effect of ginger supplementation on
cancer-related fatigue and nutritional status. Chemotherapy-induced nausea and vomiting are distressing symptoms
experienced by oncology patients; this trial will address the significant limitations within the current literature and
in doing so, will investigate the effect of ginger supplementation as an adjuvant treatment in modulating nausea
and vomiting symptoms.
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Chemotherapy-induced nausea and vomiting places a
significant burden on the patient
Despite the efficacy of cytotoxic interventions in the treat-
ment of cancer, these treatments are often accompanied
by a variety of adverse effects. Chemotherapy-induced
nausea and vomiting (CINV) is a relatively common side
effect of this treatment and has been repeatedly rated
as one of the most distressing symptoms in this setting
[1,2]. While there have been multiple classes of medica-
tions developed to treat this symptom, nausea and
vomiting persists in a large number of patients. The in-
cidence of vomiting has been significantly reduced
through combinations of anti-emetic medications, but
efforts to control nausea have been less successful. Af-
fecting upwards of 60% of patients [3], CINV has also
been shown to significantly impact on patient quality of
life (QoL). Moreover, although it happens rarely, CINV
can be so severe that it can lead to dose reduction or
treatment discontinuation, and subsequently increase
the risk of disease progression [3-5].
Ginger extract appears beneficial in treating
chemotherapy-induced nausea and vomiting
Ginger (Zingiber officinale) has been used for centuries by
many cultures as a folk-remedy for gastrointestinal-related
conditions [6]. Previous clinical trials have provided support
for its use in the treatment of nausea in multiple settings
including CINV [7-9] and two previous clinical trials have
found ginger supplementation to be as effective as metoclo-
pramide in reducing symptoms of CINV [10,11]. Further-
more, animal and cell culture data have demonstrated a
viable mechanism of action for its anti-nausea effect [12].
The rhizome of ginger possesses an array of bioactive
compounds (i.e. gingerols, shogaols, zingiberene, zinger-
one, and paradol) that may be responsible for the re-
ported beneficial effects of ginger use. Cell culture and
animal studies suggest that these constituents stimulate
oral and gastric secretions [13], regulate gastrointestinal
motility [14,15], interact with the 5-HT3 and NK-1 re-
ceptors implicated in the CINV reflex [16,17], and assist
in rescuing intracellular redox metabolism [18]. Of note,
the interaction of ginger with 5-HT3 and NK-1 receptors
is particularly promising as the success of modern anti-
emetic medications (i.e. 5-HT3 and NK-1 antagonists)
are due to similar interactions with these same recep-
tors. Furthermore, animal studies provide preliminary
support for the role of ginger supplementation in the
prevention of cisplatin-induced emesis [19,20].
A recent review found seven clinical studies have investi-
gated ginger supplementation in this setting [21]. These
studies present a contentious picture of the efficacy of gin-
ger as an anti-CINV treatment in patients administered
chemotherapy, with three demonstrating a positive effect,two in favour but with caveats, and two reporting no effect
on measures of CINV. However, multiple limitations were
identified within the existing literature that need to be re-
solved before clinical recommendations can be made.
Chemotherapy-induced nausea and vomiting poses a
significant risk to patients’ nutritional status and
treatment outcomes
Previous studies report that approximately 50% of pa-
tients in the oncology setting are malnourished [22].
Malnutrition is a serious concern for oncology patients
as it can significantly and severely affect QoL and
treatment-related outcomes. Malnutrition can result in
compromised immune function, reduced functional sta-
tus, decreased performance status, and impaired treat-
ment response [23-25]. Nausea and vomiting in this
setting are of significant concern in patients diagnosed
with cancer, as these symptoms can adversely affect diet-
ary intake, increasing the risk of malnutrition during
treatment.
It is feasible then to suggest that interventions that im-
prove nausea and vomiting during chemotherapy may
consequentially aid in improving and maintaining nutri-
tional status. However, to date, there are no studies that
have investigated the influence of ginger on patient
nutritional status in this setting. Therefore, this pro-
tocol assesses nutritional status after each cycle using
the validated questionnaire, the Patient Generated- Sub-
jective Global Assessment, performed by an accredited
dietitian.
Chemotherapy-induced nausea and vomiting might
exacerbate or be physiologically related to
chemotherapy-related fatigue
Like nausea and vomiting, chemotherapy-related fatigue
(CRF) is both highly prevalent in this population and
can significantly influence the patient’s quality of life
[26,27]. The results from a number of studies that have
investigated CRF have found nausea and vomiting to be
a strongly associated set of symptoms [28]. The reason
for this is not fully elucidated but due to this significant
correlation, treatment options that have been tradition-
ally targeted at treating CINV should be further investi-
gated as these modalities may also provide benefit to
patients experiencing CRF. Using the Functional Assess-
ment of Chronic Illness Therapies- Fatigue (FACIT-F)
subscale, our study will be the first to investigate the ef-
fect of adjuvant ginger supplementation on self-reported
measures of fatigue.
Comprehensive, validated questionnaires are required to
assess chemotherapy-induced nausea and vomiting
In order to assess CINV, the instrument used needs to
be able to accurately capture the relevant aspects of
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related, are distinct phenomena and therefore, are re-
quired to be measured as separate entities. In addition
to this, a well-developed questionnaire should be able to
provide a detailed picture of each phenomena. Widely
used questionnaires in this setting include questions that
measure multiple domains of CINV such as the severity,
the perceived intensity of CINV; frequency, the amount
of times CINV occurred over a time period; duration,
the length of time that these symptoms persisted; and
distress, the perceived burden that these symptoms place
on the patients daily function and QoL [29].
There have been several questionnaires developed for
the use of measuring nausea and vomiting, not only in
the chemotherapy setting but also in other areas. A re-
cent review identified 25 instruments that have been de-
veloped to measure nausea and vomiting in the clinical
setting [29]. The authors used a list of criteria to deter-
mine the scope of nausea and vomiting that each ques-
tionnaire was able to capture. Of all questionnaires
reviewed, no one tool fulfilled all criteria; however, the
Index of Nausea, Vomiting, and Retching (INVR) tool
was found to best meet this criteria [30].
A recent review found that only one previous study
that investigated the effect of ginger on CINV used the
INVR questionnaire [21]. This poses a significant limita-
tion to the current literature as it is plausible that in
these previous studies, ginger may have provided some
benefit to domains of CINV that were not captured by
the questionnaires employed in these respective studies.
Therefore, in order to ensure that our study is able to
capture all relevant factors involved in CINV, it is im-
portant to use a questionnaire that is both validated and
comprehensive and so it was decided that this study will
incorporate the INVR questionnaire.
Predisposing factors influence individual susceptibility to
chemotherapy-induced nausea and vomiting
Multiple factors are reported to influence the individual
risk of a patient developing CINV [31]. These factors re-
late not only to the treatment protocol but also the pa-
tient’s lifestyle, mental state, and previous experience
with nausea and vomiting in other settings [32-34]. Con-
sequently, while the emetogenicity of the treatment
protocol is the major determinant of CINV risk, a pa-
tient with multiple predisposing factors can experience
significant levels of CINV despite being prescribed a low
emetogenic chemotherapy regimen. Of particular con-
cern is the development of anticipatory nausea and
vomiting, a conditioned response that is difficult to treat,
and the gradual resistance to anti-emetic therapy after
multiple chemotherapy cycles [35].
These factors represent a significant set of potential
confounding variables for RCTs in this setting. To date,all trials in this area have recruited patients that have
already experienced nausea and vomiting in previous
chemotherapy cycles. This allows for the potential re-
cruitment of patients with an already established resist-
ance to additional anti-emetic therapies. Furthermore, if
lifestyle factors such as alcohol intake and previous ex-
perience of motion sickness, which have been shown to
influence CINV risk, are not screened for, this may re-
sult in a study comprised of two groups with a predis-
posed heterogeneous response to CINV. To date, this
has not been thoroughly controlled for and therefore,
may account for some of the difference in the results be-
tween previous trials. We have developed a short ques-
tionnaire that aims to assess these factors and will be the
first study to factor this into our post-study statistical
analysis.
Previous dosing regimens and formulations of ginger
may not have been optimal
In two recent studies that investigated the pharmacokin-
etics of multiple ginger compounds, it was found that
these compounds have a relatively short half-life of ap-
proximately 1.5-3 hours [36,37]. In order to ensure that
there are sufficient plasma levels of the active com-
pounds throughout the day, the dosage in this study is
divided between 4 capsules that will be consumed ap-
proximately every 4 hours.
The dosage of 1.2 g was selected for the following rea-
sons: 1) it is within the typical dosage utilised in previous
literature; 2) a lower dose, divided into multiple capsules,
might not reach adequate concentrations to be effective;
and 3) concerns that higher doses would reduce CINV con-
trol. Previous studies indicated higher doses were either less
effective or possibly interfered with standard anti-emetic
medications [38].
An additional limitation in the existing literature is the
inconsistent use of standardized ginger extracts. Of the
seven studies included in a recent review, only two stud-
ies used a ginger formulation that had been standardised
to the relevant bioactive compounds while the remaining
five used a crude ginger powder in capsule form [21].
The concentration of active compounds found within
preparations of ginger has been found to be highly vari-
able and can be influenced by the storage, location, and
type of processing involved in the manufacturing of a
specific ginger product [39]. Due to the majority of pre-
vious studies using unstandardized formulations, the in-
consistent results reported in the literature may be
attributed to the differences in compounds the formula-
tions used in each study.
To control for this limitation, we are using a ginger ex-
tract that has been standardised to contain 5% gingerols.
We have also arranged for a sample of our ginger capsules
to be independently analysed at the commencement and
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formulation.
Incorporating the results of these studies, we are
expanding on the current literature as the majority of
previous trials have used dosing regimens that are incon-
sistent with these findings.
Purpose of study and objectives
Purpose of study
Despite advances in anti-emetic medication, CINV con-
tinues to be a significant problem for many patients
undergoing chemotherapy and is often rated as one of
the most deleterious side-effects of cancer chemothera-
peutic treatments. There is evidence from international
trials that ginger formulations, in conjunction with
standard anti-emetic medication, can be effective in the
treatment of CINV. However, this therapy is not rou-
tinely used in oncology clinics due to its novelty and the
lack of information about how patients will tolerate gin-
ger in the clinical setting.
Hypothesis
It is hypothesised that in chemotherapy-naïve medical
oncology patients about to commence treatment of any
emetogenicity, adjuvant ginger supplementation com-
pared with placebo will:
1. Reduce the frequency, distress and duration of
chemotherapy-induced nausea (i.e. acute, delayed
and anticipatory) during each chemotherapy cycle
(up to 3 cycles).
2. Reduce frequency, distress and duration of
chemotherapy-induced vomiting and retching
3. Result in improved nutritional status, physical
function and quality of life
4. Be adhered to (>80% consumption of supplements)
and well tolerated (no significant adverse events
related to ginger supplementation).
Outcomes
Primary outcomes
 The frequency, severity, duration of acute and
delayed nausea
Secondary outcomes
 The frequency and severity of acute and delayed
vomiting
 The frequency and severity of acute and delayed
retching
 Change in ratings of cancer-related fatigue
 Adequacy of supplement blinding
 Change in nutrition status Incidence and severity of symptoms associated with
treatment
 Change in quality of life
 Change in quality of life caused by nausea and
vomiting
 Patient adherence to intervention
 Influence of previously identified factors that affect
the generation of CINV
Investigational plan
Overall study design
This study will be a double-blinded, randomised, placebo-
controlled trial. Outcomes will be assessed at three days
prior to chemotherapy, one day prior to chemotherapy, on
the day of chemotherapy, and during the 4 days post-
chemotherapy. Participants will consume the study medica-
tion for 5 days per chemotherapy cycle, commencing on
the day of chemotherapy. This will be repeated over 3
chemotherapy cycles.
Setting
The trial will be initially conducted at the Princess
Alexandra Hospital, Brisbane, Australia. Additional sites
will be utilised if further funding is obtained.
Eligibility criteria
Inclusion criteria
The following inclusion criteria will apply:
 Chemotherapy-naive patients receiving
chemotherapy of any emetogenicity level [40].
 >18 years old
 Life expectancy >3 months
 Baseline Karnofsky score >60
 No concurrent neoplasms or illness that induces
nausea independent of chemotherapy
 No self-prescribed therapies or complimentary prod-
ucts used for nausea
Exclusion criteria
The following exclusion criteria will apply:
 Patients requiring radiotherapy
 Pregnant or lactating
 Concurrent use of other ginger-containing supple-
ments and ingestion of large quantities of ginger
 History of adverse reactions to ginger
 Patients with malignancies of gastrointestinal tract/
gastrointestinal diseases or nausea and vomiting due
to reasons other than chemotherapy
 Thrombocytopenia or patients undergoing
chemotherapy that, according to physician
discretion, is likely to cause thrombocytopenia
(platelets <50 × 10^9/L)
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therapy
Study treatment
Ginger extract
The experimental treatment will be a commercial ginger
extract manufactured by Bluebonnet Nutrition [41]. This
preparation is in capsule form, and is standardised to
contain 5% gingerols. Each capsule contains 300 mg of
ginger extract with 15 mg of active ingredient per cap-
sule (60 mg per 1.2 g) within white gelatine capsules.
A regimen of 4 capsules per day will be selected in
order to incorporate the pharmacokinetics of ginger
[36,37].
Placebo
The placebo capsules will be identical to the ginger cap-
sules in appearance and will contain 300 mg of an inert
filler.
Independent analysis
The ginger capsules will be independently analysed for
the active compounds (gingerols and shogaols) by the
Southern Cross Plant Science Department at Southern
Cross University using a standardised HPLC analysis
method by the US Pharmacopeia (USP). Three random
samples will be analysed at the beginning of the trial as
well as at the end of the trial in order to assess the sta-
bility of the bioactive ingredients.
Concomitant treatment
All anti-emetic medication prescribed by the patient’s
medical team, including 5-HT3 antagonists (e.g. ondan-
setron), corticosteroids (e.g. dexamethasone), and NK1
receptor antagonists (e.g. aprepitant), will be permitted
during this trial.
Participants will be advised to avoid consuming large
amounts of dietary ginger or additional ginger capsules
as well as any other adjuvant or alternative therapy for
nausea and vomiting (excluding prescribed anti-emetic
medication) during the study period.
Large amounts of ginger is defined as consumption of
one serve of either ginger ale, crystallized ginger, or gin-
ger containing meals/products most days (4/7) of the
week for the past month; particularly within the week
before and during chemotherapy.
Withdrawal criteria
Any participant who has been randomised and then
withdraws will be included in the study on an intention
to treat basis with patient consent. If a participant with-
draws consent, data will be collected up until their time
of withdrawal. Primary outcome data will be collected in
these participants where possible.Any participant who withdraws before being rando-
mised (i.e. allocated to a particular study treatment) will
be replaced, so that the next consenting participant re-
ceives the randomisation sequence and that participant’s
allocated study treatment.
Study duration
Participants will be enrolled in the study from the time
of entry into the trial, through to 4 days after their third
chemotherapy session. It is anticipated that it will take
one year to recruit the necessary number of participants.
Treatment assignment and randomisation
Participant numbers will be assigned sequentially to par-
ticipants as soon as they sign the informed consent
form. Participants will be randomly assigned using a
computer generated randomisation sequence. The ran-
domisation sequence will be kept separately from the
study investigators and will be generated by an inde-
pendent researcher.
Methods
Recruitment
Participants will primarily be recruited through the daily
chemotherapy education sessions that are offered by the
hospital to patients who have been recently prescribed
chemotherapy. Additionally, oncology nursing staff and
chemotherapy-scheduling staff will be made aware of the
study and will be encouraged to refer patients who may
be interested in the study for further screening.
Screening
Patients will be assessed to ensure that they meet the inclu-
sion and exclusion criteria. All patients who meet the cri-
teria will be invited to participate in the study and be given
a participant information sheet. This process may occur at
any stage up to seven days prior to chemotherapy.
At the screening, patients will be informed that if they
consume large amounts of dietary ginger or additional
ginger capsules, as well as any other adjuvant or alternative
therapy for nausea and vomiting (excluding prescribed
anti-emetic medication), that this should be stopped at least
1 week prior to chemotherapy.
Questionnaires used
Rhodes Inventory of Nausea, Vomiting and Retching (INVR)
The INVR is a self-report questionnaire that measures
nausea, vomiting and retching as separate entities based
on 8 items with 5-point Likert scales [30]. The frequency
and distress of all entities is measured as well as the dur-
ation of nausea and the amount of vomitus. The tool is
suitable for use during each phase of CINV (i.e anticipa-
tory, acute, and delayed) and is designed to measure
symptoms over a 12 hour period; however, for the
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24 hours to reduce the study burden on patients. It takes
less than 5 minutes to complete.The Functional Living Index – Emesis – 5 Day Recall
(FLIE-5DR)
The FLIE-5DR is a validated nausea and vomiting-specific
self-reported outcome measure that investigates the specific
impact of chemotherapy-related nausea and vomiting on
patients’ activities of daily living [42]. It has 9 items in each
of the nausea and vomiting scales, the first item of which
rates the extent of nausea or vomiting experienced in the
previous 5 days. The remaining items examine patients’ so-
cial, recreational and leisure activities, ability to do normal
tasks, their enjoyment of eating and drinking, and the hard-
ship caused by their nausea and vomiting on themselves
and their carers. Each response is ranked on a seven point
scale. The FLIE score is determined by summing the re-
sponses to the 9 questions in each scale. Therefore, the
range of total scores possible per scale is 9 to 63, with a
higher score responding to less hardship and less impact of
nausea or vomiting on daily life [42]. No or minimal impact
on daily life is defined as an average FLIE item score of no
more than 6 on the 7 point scale or a total FLIE score of
more than 54 [42]. The FLIE has excellent internal reliabil-
ity, with a Cronbach’s α > 0.90 for both sub-scales on all as-
sessment points [43,44]. The FLIE takes less than 2 minutes
to complete.CINV susceptibility questionnaire
This questionnaire has been developed for use in this
trial to determine participants’ predisposition to CINV.
Previous research has reported several factors correlated
with susceptibility to CINV. These include lifestyle
factors (e.g. alcohol intake); previous experience of nau-
sea and/or vomiting from causes other than chemother-
apy (e.g. motion sickness, pregnancy); and participant
characteristics (e.g. age, gender). It is estimated that
the questionnaire takes approximately 5 minutes to
complete.Edmonton Symptom Assessment System (ESAS)
The ESAS is a validated and reliable tool used to assess
the severity of common symptoms experienced by can-
cer patients including pain, anxiety and drowsiness. It
includes 10 items that are self-assessed by the patient
using individual 10-point scales. This tool has been vali-
dated in this population and has reported a Cronbach’s
α of 0.79 [45]. The tool will be administrated at -1 day
and at 4 days post-chemotherapy for each cycle in order
to determine treatment related side-effects. The tool
should take approximately 5 minutes to complete.Patient Generated - Subjective Global Assessment
(PG-SGA)
Nutritional status will be measured using the valid and reli-
able scored PG-SGA [46]. Using the data gained from this
tool, statistical analysis will be conducted to determine the
impact of CINV on the participants’ nutritional status. The
PG-SGA will be conducted by a dietitian who has under-
gone training and testing for inter-rater reliability on nutri-
tional status measures. The PG-SGA is specifically designed
to assess the nutritional status of cancer patients. This tool
provides a global rating of either A (well nourished), B (sus-
pected or moderately malnourished) or C (severely mal-
nourished). This global rating is based upon weight change,
dietary intake, GI symptoms, a physical examination and
the patient’s functional capacity. A total PG-SGA score is
also calculated. A higher score reflects a higher risk of mal-
nutrition and an increased need for nutrition intervention
and symptom management.
Functional Assessment of Cancer Therapy- General
(FACT-G) and Fatigue (FACIT-F) subscale
The participants’ self-assessed QoL will be measured using
the FACT-G questionnaire, a validated tool that has been
widely used in this setting [47]. It contains 27 questions
with a 5-point scale, which assesses four domains of patient
QoL: physical well-being, social/family well-being, emo-
tional wellbeing, and functional well-being. Strong concur-
rent validity with the Functional Living Index-Cancer tool
was demonstrated with a Pearson coefficient of 0.79 [47].
Additionally, we have included the Functional Assessment
of Chronic Illness Therapy- Fatigue (FACIT-F) subscale, a
13 item Likert scale, to assess self-reported symptoms of fa-
tigue before and after each chemotherapy cycle. It is esti-
mated to take between 5-10 minutes to complete.
Adherence questionnaire
To assess the level of adherence to the study protocol, a
questionnaire was developed for patients to record if
and when they consumed the ginger/placebo doses per
day. This is achieved by either recording the time or
marking an X, depending on whether they consumed
each dose, in the box corresponding to the dose in ques-
tion. This is to be completed each day and is expected
to take less than 2 minutes to complete.
Timeline
The details of the study procedure are detailed below in
chronological order. This timeline contains the details of
the study process per cycle and will be repeated for 3 cy-
cles (Figure 1).
Pre chemotherapy – 7 days prior to chemotherapy
The researcher will see patients as close as possible to 7 days
prior to chemotherapy to determine their eligibility. If the
Figure 1 Study flow diagram.
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tained, the details of the study will be explained, and the
supplements and questionnaire booklet will be delivered.
Participants will be provided with written information and
educated regarding the consumption of the supplement.
Participants will be randomised and provided with a
5 day (4 × 300 mg capsules per day) supply of ginger
extract (20 capsules) or the placebo control (20 cap-
sules) to be consumed daily with liquid in addition to
their usual diet for 4 days, starting on the day of
chemotherapy. The supplement will be provided in a
sealed plastic container that will be packed by a re-
searcher not involved in data collection.
Participants will be given a booklet containing the self-
report questionnaires for CINV, QoL, adverse events, and
blinding for the full study period per chemotherapy cycle
(5 days). Each booklet will contain:
 One INVR questionnaire per day: one on the day of
chemotherapy, and one each of the 4 days post-
chemotherapy.
 Two FACT-G/FACIT-F questionnaires per cycle.
 One FLIE-5DR questionnaire per cycle. Two ESAS questionnaire.
 One CINV susceptibility questionnaire.
 One Adherence Questionnaire for each day the
participant receives the study medication: one on
the day of chemotherapy, and one for each of the
4 days post-chemotherapy.
 Instructions on how and when to complete these
questionnaires will be included, as well the contact
details of the study investigators.
During this consultation, the participant’s nutritional
status will also be assessed using the PG-SGA assess-
ment tool.
Pre chemotherapy – 1 day prior to chemotherapy
The following tools will be completed by the participant
24 hours before chemotherapy:
 One FACT-G/FACIT-F questionnaire
 One ESAS questionnaire
Day of chemotherapy
The following tools will be completed by the participant
on the day of chemotherapy:
 One INVR questionnaire will be completed before
chemotherapy commences.
 One CINV susceptibility questionnaire will be
completed any time after chemotherapy has
commenced.
 One adherence questionnaire.
Additionally, the participant is to consume one gin-
ger/placebo capsule 1 hour before the administration
of chemotherapy and then once every 4 hours after
that for the remaining 3 capsules. The timing will be
discussed with the participant to help ensure the par-
ticipant understands the regimen.
Post-chemotherapy – day 1-4 post-chemotherapy
During the 4 days post-chemotherapy, participants will
be asked to complete:
 One INVR questionnaire per day. The timing of
completion should be at the same time of day as
when they completed their previous questionnaire.
This will ensure that 24 hours is assessed per
questionnaire.
 One adherence questionnaire.
 The participant will consume 4 capsules per day.
One before breakfast, one before lunch, one
during an afternoon snack, and one before dinner.
These capsules are to be consumed one hour
before each meal.
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At the end of day 4, participants will be asked to complete:
 One FACT-G/FACIT-F questionnaire
 One FLIE-5DR questionnaire
 One ESAS questionnaire
 One adherence questionnaire
Supplements are consumed using the same schedule
as above.
At the end of day 4, participants will no longer be re-
quired to consume the oral supplements and any uncon-
sumed supplements, along with the questionnaire booklet,
will either be collected by the research team, along with the
participant questionnaire booklet, during the participant’s
next visit to the hospital or sent directly to the researchers
using a reply-paid envelope. Unconsumed supplements of
each individual will be counted in order to determine their
level of adherence to the study protocol.
Assessment of blinding
At the end of day 4, the investigator will contact each
participant to obtain information regarding the study
blinding. This will be determined by asking each partici-
pant the following questions: “Do you think you received
the placebo or the ginger supplement and why do you
think this?”. Participants will also be asked if they have
any comments or queries regarding the trial so as to
gather feedback for the improvement of the study proto-
col for future trials.
The timing of the participant’s next chemotherapy cycle
will also be discussed and arrangements will be made to
meet within the week before chemotherapy in order to dis-
pense additional supplements and assessments.
Statistical analysis
Analyses will be conducted according to intention-to-treat
principles i.e. the consent process will maximise outcome
data collection and attempt to assess nausea symptoms for
everyone, and will retain original group allocation despite
actual compliance levels.
Participants will be block stratified by chemotherapy
category (i.e. minimal, low, moderate and high emeto-
genicity) then randomised within strata into intervention
and control groups (Figure 1) [48].
Descriptive statistics will be presented as mean ± standard
deviation, or median with range, as appropriate. Parametric
analyses will be used for all continuous variables. Chi-
square analyses will determine associations between cat-
egorical variables. For example, the incidence, severity and
type of nausea and vomiting between the two groups. Pear-
son correlation analysis of continuous variables will be per-
formed. Repeated measures analyses will be conducted to
detect between group differences over time as per ourstatistician recommendations. Statistical significance will be
set at p < 0.05 level (two-tailed). Data will be analysed using
SPSS for Windows version 22 (Statistical Package for Social
Sciences, IL, USA).
Sample size
A sample size calculation for comparing two means with
unpaired t-tests based on the reductions in the preva-
lence of chemotherapy-induced nausea reported by
Panahi et al. [49], estimates that 73 participants would
be required in the intervention and control groups (i.e.
total of N = 146) to detect this difference with 80 per
cent power at the 95 per cent significance level (two
tailed).
Approximately 250 patients receive moderately emeto-
genic chemotherapy and 240 patients receive highly
emetogenic chemotherapy at Princess Alexandra Hos-
pital each six months (1/3-1/9/2012) which indicates
that the required sample size is obtainable in this study.
Ethical considerations
The study protocol has been approved by the Metro
South Human Research Ethics Committee on the 4th of
July, 2013. The trial has also been registered with the
Australian New Zealand Clinical Trials Registry and has
been assigned the identifier, ACTRN12613000120774.
The study complies with the Declaration of Helsinki
rules and the principles of Good Clinical Practice guide-
lines. Informed consent will be gained from all partici-
pants before commencing the trial and patient data will
be stored securely. Participants will also be monitored
for adverse effects and will be discontinued immediately
if the study protocol is determined to be causing harm
or if the participant chooses to withdraw. This study re-
ceived grant funding from the Queensland Health –
Health Practitioner Scheme.
Discussion
This study protocol expands on the current literature re-
garding the efficacy of ginger as an adjuvant therapy for
CINV. Recommendations for the use of ginger in the on-
cology setting are premature, as previous reviews have
shown inconsistent results and have possessed several limi-
tations. Primary concerns identified in the literature include
the lack of control of anticipatory nausea, the inconsistent
use of standardised ginger extracts and validated assess-
ments tools, and a lack of assessment for prognostic factors
that may influence individual CINV response [21]. Add-
itionally, recent pharmacokinetic studies demonstrate that
the half-life of the active compounds within ginger are rela-
tively short-lived, which suggests that the dosing regimens
employed by previous studies may be suboptimal. Further-
more, multiple studies included in these reviews have used
anti-emetic therapies that are not congruent with current
Marx et al. BMC Complementary and Alternative Medicine 2014, 14:134 Page 9 of 11
http://www.biomedcentral.com/1472-6882/14/134best practice and anti-emetic guidelines and therefore, the
application of these previous findings to current practise
are further diminished [21,48].
In designing our trial, we aimed to address these
limitations while incorporating elements of rigorous
study methodology that have been incorporated in
previous trials in this area. For example, our trial will
be using multiple, validated assessment tools along
with a standardised ginger extract, both of which have
been utilised in at least two previous trials [50,51].
We will, however, expand on this by independently
analysing our extracts at both the beginning and
end of our recruitment phase to ensure consistent
potency.
It should also be noted that one study by Ryan et al. [51]
found ginger to reduce CINV when ginger supplementa-
tion was commenced three days before chemotherapy. We,
however, decided against using this methodology and opted
for ginger supplementation commencing on the day of
chemotherapy due to the following reasons. Firstly, there
have been multiple previous trials using ginger for CINV as
well as other forms of nausea that did not use the regimen
used by Ryan et al. [51] but rather a timeframe and dosage
more closely resembling the regimen in our protocol that
yielded beneficial results [49,52-54]. In addition to this, to
date, there has been no research that has investigated the
regimen used in the Ryan et al. [51] study compared to the
more typical dosing regimen that has been employed in our
study, which restricts one from determining the superiority
of said regimen. Lastly, the basis for said regimen, from our
research and from the discussion in the Ryan et al. [51]
paper, seems to have been implemented largely on a
theoretical basis and therefore, until more evidence arises,
we have decided to instead opt for the more patient-
convenient regimen described in this manuscript.
Our trial will also be the first to introduce multiple
novel study design elements. Primarily, our study will
be the first to recruit only chemotherapy-naive pa-
tients. This strategy should mitigate the significant
limitation of anticipatory nausea. It is a response to
previous research reporting that CINV control pro-
gressively deteriorates with each subsequent chemo-
therapy cycle, if not adequately controlled during the
initial cycle [35]. Due to the association between fa-
tigue and nausea in this setting, we will also investi-
gate the effect that ginger has on this association in
order to determine if ginger may be of benefit to pa-
tients also experiencing cancer-related fatigue. Finally,
our study will also implement a dosing regimen that is
consistent with the findings of the previously mentioned
pharmacokinetic studies that will likely improve the
CINV protection of this therapy. If successful, this trial
will provide support for the efficacy of ginger as a vi-
able adjuvant anti-emetic therapy and in doing so, helpmanage chemotherapy symptoms and assist in improv-
ing patient QoL.
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